|
Feb 23
|
Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts
|
|
Feb 20
|
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
|
|
Feb 20
|
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics
|
|
Feb 20
|
Amicus Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
|
|
Feb 20
|
Amicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Feb 20
|
Q4 2024 Amicus Therapeutics Inc Earnings Call
|
|
Feb 19
|
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates
|
|
Feb 19
|
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
|
|
Feb 17
|
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
|
|
Feb 17
|
Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics
|
|
Feb 13
|
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
|
|
Feb 12
|
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
|
Feb 10
|
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
|
|
Jan 2
|
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|